I dig around and found this old post on HC from 2008. https://hotcopper.com.au/threads/osiris-vs-mesoblast-mesenchymal-stem-cells.791600/ The post outline the difference between MSC from Osiris and MSB. From my understanding, they are different. Therefore the objection based on Osiris' trial failure should be irrelevant. Any thoughts?
Ann: FDA Advisory Committee Sets Review Date for Remestemcel-L, page-164
-
- There are more pages in this discussion • 691 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
95.0¢ |
Change
0.025(2.70%) |
Mkt cap ! $1.101B | |||
| Open | High | Low | Value | Volume |
| 94.0¢ | 96.5¢ | 93.5¢ | $2.193M | 2.296M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 13 | 112752 | 94.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 95.0¢ | 93985 | 16 |
View Market Depth
| Last trade - 12.05pm 09/08/2024 (20 minute delay) ? |
| MSB (ASX) Chart |